RGD Reference Report - Effects of C1 inhibitor on endothelial cell activation in a rat hind limb ischemia-reperfusion injury model. - Rat Genome Database

Send us a Message

Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

Effects of C1 inhibitor on endothelial cell activation in a rat hind limb ischemia-reperfusion injury model.

Authors: Zhang, Shengye  Shaw-Boden, Jane  Banz, Yara  Bongoni, Anjan K  Taddeo, Adriano  Spirig, Rolf  Nolte, Marc W  Cowan, Peter J  Rieben, Robert 
Citation: Zhang S, etal., J Vasc Surg. 2018 Jan 27. pii: S0741-5214(17)32653-8. doi: 10.1016/j.jvs.2017.10.072.
RGD ID: 13525001
Pubmed: (View Article at PubMed) PMID:29395422
DOI: Full-text: DOI:10.1016/j.jvs.2017.10.072

OBJECTIVE: Ischemia-reperfusion (I/R) injury is a major clinical problem linked to vascular surgery. Currently, no drugs to prevent or to treat I/R injury are approved for clinical use. C1 inhibitor (C1 INH) is known to reduce activation of the plasma cascade systems that are involved in the pathophysiologic process of I/R injury. The aim of this study was therefore to investigate the effect of C1 INH on complement deposition and endothelial cell activation in a rat model of hind limb I/R injury.
METHODS: Male Wistar rats (wild type, bred at the central animal facility, University of Bern), weighing 250 to 320 g, were used. The rats underwent 2-hour ischemia and 24-hour reperfusion by unilateral clamping of the femoral artery and additional use of a tourniquet. Five groups were divided according to intravenous treatment 5 minutes before ischemia: 50 IU/kg C1 INH (n = 5); 100 IU/kg C1 INH (n = 7); vehicle control (n = 5); nontreated control (n = 7); and normal, healthy control without intervention (n = 4). At the end, muscle edema, tissue viability, and histologic features were assessed. Deposition of immunoglobulin M, C1r, C4d, and fibrin and expression of plasminogen activator inhibitor 1, heparan sulfate (HS), E-selectin, and vascular cell adhesion molecule 1 were evaluated by fluorescence staining. In addition, high-mobility group box 1 protein was measured in plasma.
RESULTS: Edema formation was reduced by C1 INH at two dosages, mirrored by improved histologic injury scores and preserved muscle viability. Deposition of immunoglobulin M, C4d, and fibrin was significantly decreased by 100 IU/kg C1 INH compared with nontreated controls. Pretreatment with 100 IU/kg C1 INH also significantly reduced HS shedding and expression of plasminogen activator inhibitor 1 as well as plasma levels of high-mobility group box 1 protein.
CONCLUSIONS: Pretreatment with both 50 and 100 IU/kg C1 INH attenuated reperfusion injury of rat hind limbs. Pretreatment with 100 IU/kg also preserved the endothelial HS layer as well as the natural, profibrinolytic phenotype of the endothelium. Prevention of endothelial cell activation by C1 INH may therefore be a promising strategy to prevent I/R injury in the clinical setting of peripheral vascular diseases and elective surgery on extremities.

Disease Annotations    

Objects Annotated

Genes (Rattus norvegicus)
Serping1  (serpin family G member 1)

Genes (Mus musculus)
Serping1  (serine (or cysteine) peptidase inhibitor, clade G, member 1)

Genes (Homo sapiens)
SERPING1  (serpin family G member 1)

Additional Information